Seattle Genetics (SGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	7/15/2011 12:11:42 PM
	of 161

Seattle Genetics Inc. to discuss the ODAC Recommendations - Conference call Fri, Jul 15, 2011, 8:30 am Eastern Archive of the call is available: investor.seagen.com Shares of Seattle Genetics SGEN -7.55% fell 11% to $18.09 on concerns that the U.S. launch of its new oncology drug Adcentris might be delayed because of a regulatory snag. On Thursday, an advisory panel of the U.S. Food and Drug Administration voted to recommend conditional approval of the drug for the treatment of two types of lymphoma under the agency's acclerated approval program. The drug's final approval would be dependent on the satisfactory completion of certain clinical studies. According to Dow Jones Newswires, agency officials still have not determined what types of studies they will require, which could result in the drug's conditional approval being delayed past the expected Aug. 30 deadline. While the FDA is not bound to the recommendations of its panels, it generally follows them.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next